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86 The Journal of Thoracic and Cardiobjective: Non–small cell lung cancer with pulmonary metastasis in the primary
obe (PM) is classified as pathologic stage IIIB. Although stage IIIB PM
ndicates a poor prognosis, this stage includes various subgroups with heteroge-
eous clinical outcomes. The objective of this study was to extract a subgroup of
atients with stage IIIB PM non–small cell lung cancer with a better prognosis and
ssess their biological characteristics and metastatic mechanisms.
ethods: We reviewed 122 cases of surgically resected stage IIIB PM non–small
ell lung cancer and extracted a subgroup with a favorable outcome by univariate
nalysis of clinicopathologic factors. The 15 cases without lymph node metastasis
nd vessel invasion (PM/N/VI) were extracted as the most favorable group.
e assessed the clinicopathologic features of the PM/N/VI group in compar-
son with the other patients with stage IIIB PM disease.
esults: The disease-specific survival of the PM/N/VI group was significantly
etter than that of the other stage IIIB PM group. Microscopic characteristics of
he metastatic lesions suggesting that the cancer cells had invaded via the aeroge-
ous route were seen in 86.7% of the PM/N/VI group, as opposed to only
.4% of the other PM cases. Furthermore, in all 4 patients in the PM/N/VI
roup who had a recurrence, the relapse involved intrapulmonary metastasis, rather
han distant organ metastasis.
onclusions: Stage IIIB PM cases via the airway route were enriched in the
M/N/VI group and had an extremely good survival. This group should be
ecognized as having local disease, and if relapse occurs in the remnant lobe, it may
e possible to achieve a cure by local therapy.
atients with pathologic stage IIIB non–small cell lung cancer (NSCLC) have
a poor prognosis even after complete resection, and they have been reported
to have a 15% to 20% 5-year survival.1–3 Intrapulmonary metastasis by
rimary NSCLC, even within the same lobe as the primary cancer, is an independent
nfavorable factor and is classified as T4. Patients with intrapulmonary metastasis
ave been categorized as having stage IIIB disease since the revision of the TNM
taging system in 1997.4 However, some investigators have reported that the
rognosis of patients with intrapulmonary metastasis is more accurately reflected by
lassifying their disease as T3,5,6 whereas others recommend upgrading the tumor
tatus.7–9 Despite numerous studies, the prognostic significance of intrapulmonary
etastasis is still a matter of controversy. The controversy may be attributable to the
ifferent mechanisms of intrapulmonary metastasis. Three possible mechanisms of
ntrapulmonary metastasis have been postulated: (1) via the lymphatic vessel route,
2) via the blood vessel route, or (3) via the airway route.7 Armed Forces Institute
vascular Surgery ● August 2007
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G
TSf Pathology text describes metastasis by the airway route
s aerogenous spread.10 Two of these metastatic mecha-
isms, the lymphatic and hematogenous spread by cancer
ells, increase the chance of remote organ metastasis. Cir-
ulating tumor cells have a greater possibility of invading
istally, and several investigators have actually described a
ositive correlation between vessel invasion and distant
etastasis or recurrence.11–15 On the other hand, a process
n which tumor cells shed at the primary site implant and
orm a separate tumor via the airway route, namely aerog-
nous spread, is sometimes observed in primary lung can-
er.10,16 Therefore, NSCLC with intrapulmonary metastasis
ia the aerogenous route might be regarded as local disease
ecause of the absence of systemic dissemination via lymph
essels and blood vessels.
The objective of the present study was to extract a
ubgroup of NSCLC patients with pathologic stage IIIB
isease who have a better outcome and analyze this
ubgroup from the standpoint of its biological character-
stics and metastatic mechanisms, especially via the air-
ay route.
atients and Methods
atient Selection
mong the 1912 consecutive patients with NSCLC who under-
ent complete surgical resection at the National Cancer Center
ospital East between July 1992 and December 2004, 146 patients
ad pathologic stage IIIB disease, and in 122 (83.6%) of them the
iagnosis was stage IIIB disease because they had satellite mod-
les in the same lobe as the primary lung cancer (PM).
Complete resection was defined as absence of residual can-
er grossly and histologically. Patients with a positive surgical
argin or who underwent limited resection for NSCLC were
xcluded as subjects of this study. The data collection and
nalysis were approved by the institutional review board in
anuary 2006, and it waived the need to obtain informed con-
ent from each patient.
istologic Studies
he surgical specimens were fixed with 10% formalin and embed-
ed in paraffin. Serial 4-m sections were stained with hematox-
lin and eosin, by the Alcian blue–periodic acid–Schiff method for
ytoplasmic mucin production, and by the elastica van Gieson or
ictoria blue van Gieson stain method for elastic fibers. All
istologic materials included in the series were initially assessed
y pathologists. The materials were subsequently reviewed by two
athologists (K.A. and G.I.) to ascertain the presence of pulmonary
Abbreviations and Acronyms
NSCLC non–small cell lung cancer
PM  pulmonary metastasis
UICC  International Union Against Canceretastasis and assess the histopathologic features of both the C
The Journal of Thoracicrimary tumors and pulmonary metastases. Intrapulmonary metas-
asis was defined as the following features. First, there were many
oating cancer cells separating from and around the primary
umor. Second, the histologic characteristics and cytologic mor-
hology, including cell size and nuclear atypia, were similar to
hose of primary cancer cells.17 Lymphatic permeation was con-
idered to be present when tumor cells floating in lymphatic
essels with no supporting smooth muscles or elastic fibers were
dentified. Vascular invasion was considered to be present when
umor cells floating in blood vessels with supporting elastic fibers
ABLE 1. Subsets of 146 patients with pathologic stage
IIB disease
Stage IIIB No. of patients
T4 N0 M0
PM 3 (2.1)
PM 52 (35.6)
T4 N1 M0
PM 5 (3.4)
PM 16 (11.0)
T4 N2 M0
PM 9 (6.2)
PM 52 (35.6)
T4 N3 M0
PM 0 (0)
PM 2 (1.4)
T1 N3 M0 3 (2.1)
T2 N3 M0 3 (2.1)
T3 N3 M0 1 (0.7)
M/, With/without satellite tumor nodules within the ipsilateral primary-
umor lobe of the lung. Numbers in parentheses are percentages.
ABLE 2. Clinical characteristics in the 122 patients with
athologic stage IIIB PM
haracteristics No. of patients P value*
ex
Male 73
Female 49 .554
ge (y)
70 75
70 45 .985
moking history (pack-year)
20 60
20 62 .558
moking history
Never smoker 43
Smoker 79 .402
reoperative CEA value (ng/mL)
5.0 62
5.0 60 .123
esection
Pneumonectomy 7
Lobectomy 115 .235EA, Carcinoembryonic antigen. *Log–rank test.
and Cardiovascular Surgery ● Volume 134, Number 2 387
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TSere identified. Some serial sections were stained by the Victoria
lue van Gieson stain method to help recognizing elastic fi-
ers.12,18 Histologic typing was performed according to the World
ealth Organization classification of cell types.19 Pathologic stage
as determined on the basis of the TNM classification of the
nternational Union Against Cancer (UICC).20
tatistical Analysis
ifferences in patient characteristics between the 2 populations
ere tested for significance by the Pearson 2 test or Fisher exact
est. For the univariate analysis, all cumulative survivals were
stimated by the Kaplan–Meier method, and differences in vari-
bles were calculated by the log–rank test. All P values reported
re 2-sided. The analyses were performed with the SPSS 11.0
tatistical software program (Dr. SPSS II for Windows, standard
ersion 11.0, SPSS Inc, Chicago, Ill).
esults
he distribution of the 146 cases classified as pathologic
tage IIIB is shown in Table 1, and 122 (83.6%) cases were
lassified as stage IIIB for the presence of intrapulmonary
etastasis. Overall follow-up time of the censored patients
anged from 1.2 to 132.0 months, and the median value was
8.3 months. Univariate analysis of postoperative survival
tratified according to 6 clinical and 7 pathologic factors
evealed significant differences in the following factors:
ymph node metastasis, vascular invasion, and lymphatic
ermeation (Tables 2 and 3). Among the 122 patients with
M in pathologic stage IIIB, a subgroup of 15 (12.3%)
atients with a better outcome was selected according to the
ABLE 3. Pathologic characteristics in the 122 patients
ith pathologic stage IIIB PM
haracteristics No. of patients P value*
ominant histologic type
Adenocarcinoma 94
Non-adenocarcinoma 28 .666
ifferentiation
Well 25
Moderately or poorly 97 .891
ymph node metastasis
N () 52
N () 70 .002†
ymphatic permeation
Ly () 40
Ly () 82 .006†
ascular invasion
V () 36
V () 86 0.021
leural invasion
P () 62
P () 60 0.141†
Log–rank test. †P  0.05.avorable clinicopathologic factors: no lymph node metas- e
88 The Journal of Thoracic and Cardiovascular Surgery ● Auguasis (N) and no vessel invasion (VI). The survivals of
his subgroup (PM/N/VI) and the other stage IIIB
M subgroup are compared in Figure 1, A. The PM/
/VI group had a much better outcome, that is, a 91.7%
-year disease-specific survival, and the log–rank test
howed a significant differences from the other stage IIIB
M cases (P  .0042). Additionally, the PM/N/VI
roup also had significantly better disease-specific survival
han the other stage IIIB group (P  .0028; Figure 1, B).
We considered that cancer cells with lepidic growth and
o destruction of bronchovascular bundles and alveolar
epta in the metastatic foci might have resulted from aerog-
igure 1. A, Disease-specific survival curve of the PM/N/VI
roup and the other stage IIIB PM group. B, Disease-specific
urvival curve of the PM/N/VI group and the other stage IIIB
roup.nous spread (Figure 2, A and B),10,16,21 whereas cancer
st 2007
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G
TSells that had formed solid nests and destroyed neighboring
lveolar septa as they grew (Figure 2, C and D) had not
esulted from aerogenous metastasis. Table 4 shows the
requency of the characteristic histologic findings of aerog-
nous spread in the metastatic cancers. Significantly higher
ates of histologic findings of aerogenous spread were found
n the PM/N/VI group (86.7%) than in the other stage
IIB PM group (9.4%; P  .001).
Comparisons of the clinicopathologic characteristics of
he PM/N/VI group and the other stage IIIB PM
ABLE 4. Histopathologic feature of pulmonary metastatic
oci with pathologic stage IIIB
epidic growth without
estruction of
ronchovascular bundles
Figure 2, A and B)
Patients with pathologic
stage IIIB PM (n  122)
P value*
PM/N/VI
(n  15)
The others
(n  107)
ositive 13 (86.7) 10 (9.4) .001
egative 2 (13.3) 97 (90.7)wFisher exact test; Numbers in parenthesis are percentages.
The Journal of Thoracicroup are summarized in Table 5. Compared with the other
tage IIIB PM group, the PM/N/VI group contained
higher percentage of women (P  .005), a lower per-
entage of smokers (P  .007), had a lower serum
arcinoembryonic antigen level (P  .016), a higher
ncidence of well-differentiated tumors (P  .001), and a
ower rate of pleural invasion (P  .003). These factors
ere not significant prognostic factors by univariate anal-
sis among stage IIIB PM patients indicated in Tables 2
nd 3. The histologic type of primary tumors in the PM/
/VI group was adenocarcinoma in every case (P 
021). Four were the mucinous bronchioloalveolar carci-
oma dominant subtype and 11 were the papillary dom-
nant subtype.
All 4 of the 15 patients with recurrence had pulmonary
etastasis in the remnant lung and no distant metastases
espite having stage IIIB disease.
iscussion
his study is the first report identifying the favorable subset
Figure 2. Histopathologic features of a tumor
that metastasized by aerogenous spread. A, Can-
cer cells with lepidic growth but no destruction
of bronchovascular bundles and alveolar septa
in the metastatic foci. The black arrows point to
normal bronchial epithelium adjacent to the can-
cer cells (hematoxylin-eosin stain; original mag-
nification, 40). B, Higher magnification view of
part A. Elastic fibers of the alveolar septa can be
clearly seen, indicating the absence of destruc-
tion of the pulmonary parenchyma. (Victoria blue
van Gieson stain; original magnification, 40).
C, Cancer cells have formed a solid nest and de-
stroyed the pulmonary parenchyma (hematoxylin-
eosin stain; original magnification, 40). D, Higher
magnification view of part C. Prominent disrup-
tion of elastic fibers is seen, indicating destruc-
tion of the pulmonary parenchyma (Victoria blue
van Gieson stain; original magnification, 40).ithin stage IIIB and PM patients and analyzing its char-
and Cardiovascular Surgery ● Volume 134, Number 2 389
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TScter by careful histologic examination. The PM/N/VI
roup that we extracted had significantly better disease-
pecific survival than the other pathologic stage IIIB PM
atients (91.7% vs 44.5%). Their survival was almost the
ame as or better than that of patients with pathologic stage
A disease.2,3 Of course, this group had a significantly better
utcome than had the patients with pathologic stage IIIB
isease. This subgroup as a whole had the biological char-
cteristics described below.
First, the clinicopathologic background of this subgroup
ABLE 5. Characteristic comparison of 15 patients with
M/N/VI and the other 107 patients with pathologic
tage IIIB PM
haracteristics
Patients with pathologic
stage IIIB PM (n  122)
P value*
PM/N/VI
(n  15)
The others
(n  107)
ex 4 69
Male
Female 11 38 .005*
ge (y)
70 7 70
70 8 37 .159*
moking history
(pack-year)
20 13 47
20 2 60 .002*
moking history
Never smoker 10 33
Smoker 5 74 .007*
reoperative CEA value
(ng/ml)
5.0 12 50
5.0 3 57 .016*
esection
Pneumonectomy 2 5
Lobectomy 13 102 .206†
ominant histologic type
Adenocarcinoma 15 79
Nonmucinous BAC 0 32
Mucinous BAC 4 1
Acinar 0 6
Papillary 11 27
SA with mucin 0 13
Nonadenocarcinoma 0 28 .021†
ifferentiation
Well 10 15
Moderately or poorly 5 92 .001†
leural invasion
P () 13 49
P () 2 58 .003*
EA, Carcinoembryonic antigen; BAC, bronchioloalveolar carcinoma; SA,
olid adenocarcinoma. *Pearson 2 test. †Fisher’s exact test.as clearly different from that of the other stage IIIB PM b
90 The Journal of Thoracic and Cardiovascular Surgery ● Auguroups. It contained a significantly higher percentage of
omen, a lower percentage of smokers, and a higher per-
entage of well-differentiated tumors. All of the primary
umors were adenocarcinoma, and the dominant subtypes
ere mucinous bronchioloalveolar carcinoma in 4 cases and
apillary subtype adenocarcinoma in 11.
Second, the microscopic findings characteristic of aerog-
nous metastasis were significantly more common in the
M/N/VI group.10,21
Third, all 4 patients who had a recurrence among the 15
atients in the PM/N/VI group had pulmonary metas-
asis in the remnant lung and no distant metastasis, despite
aving stage IIIB disease.
On the basis of these results, we speculated that pulmo-
ary metastasis of the PM/N/VI group might be
aused by the mechanism of aerogenous metastasis, and this
roup would indicate extremely good survival. The major
echanism of metastasis of primary adenocarcinoma of the
ung to the lung includes hematogenous and/or lymphatic
pread. However, unlike other organs targeted as the meta-
tatic site, the lung displays characteristic anatomic struc-
ure, which causes another metastatic mechanism—aeroge-
ous spread. The molecular biological mechanism of this
athway has been elucidated by Kodama and associates.16
hey clearly showed the important role of laminin 5 expres-
ion in aerogenous spread and lepidic growth by adenocar-
inoma cells in an animal model and in resected human lung
arcinomas. This molecular approach has provided insight
nto the mechanism of aerogenous spread in the PM/N/
I group. Although the current data suggest a biological
asis for aerogenous spread, this mechanism remains in-
ompletely proven. However, we consider that this study
ill be important to investigate the further biological mech-
nisms of aerogenous metastasis.
NSCLC with intrapulmonary metastasis to the primary
obe via the airway route should be regarded as local dis-
ase, not as systemic disease. Thus, it might be better to
lassify the PM/N/VI group as having local disease,
ot systemic disease. This subgroup should be clearly dif-
erentiated from other stage IIIB groups.
onclusions
n the present study, we were able to extract a subgroup
PM/N/VI) with an extremely good outcome from
atients undergoing surgically resected NCSLC with patho-
ogic stage IIIB disease. This PM/N/VI group is clas-
ified as having stage IIIB disease, but because the pulmo-
ary metastasis in this group appears to occur via the airway
oute, this group should be regarded as having local disease.
he efficacy and role of postoperative adjuvant chemother-
py in the treatment of patients having surgically resected
SCLC with pathologic stage IIIB disease remains unclear,
ut some researchers recommend adjuvant chemotherapy
st 2007
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G
TSfter surgery.22–24 Although a prospective study with a
arger number of patients in a multicenter study is war-
anted, it might be considered that this population is highly
urable by local therapy alone without systemic adjuvant
herapy. Additionally, if relapse occurs in the remnant lobe,
here may be a possibility of cure by local therapy if
ulmonary function permits.
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